8-K: Flotek Reports 95% Gross Profit Growth in Q3 2025

Flotek Industries announced strong third-quarter 2025 financial results, driven by a 95% gross profit increase and significant growth in its Data Analytics segment, leading to increased full-year guidance.

Summary

• Total revenues increased 13% to $56.0 million in Q3 2025, and 25% to $169.7 million for the nine months ended September 30, 2025.
• Gross Profit surged 95% to $17.8 million in Q3 2025, and 65% to $44.6 million for the nine months ended September 30, 2025.
• Net Income dramatically increased 704% to $20.4 million, or $0.53 per diluted share, in Q3 2025, and 353% to $27.5 million, or $0.78 per diluted share, for the nine months ended September 30, 2025.
• Adjusted EBITDA grew 142% to $11.7 million in Q3 2025, marking the twelfth consecutive quarter of growth, and 118% to $28.9 million for the nine months ended September 30, 2025.
• Data Analytics segment revenues grew 232% to $8.9 million in Q3 2025, now representing 16% of total revenues, up from 5% in Q3 2024.
• Chemistry Technologies external revenues grew 43% in Q3 2025 despite a 25% year-over-year decline in North American frac fleets.
• The company increased its 2025 guidance: Total Revenues to $220-$225 million (from $200-$220 million) and Adjusted EBITDA to $35-$40 million (from $34-$39 million).
• Q3 2025 net income included a $12.6 million tax benefit related to previously reserved deferred tax assets.
• The XSPCT™ analyzer was the first optical spectrometer to comply with GPA 2172 (O&G Custody Transfer Standard).
• PWRtek™ (Acquired Assets) generated $6.1 million in Q3 2025 revenue with an 89% gross profit margin, and all assets were in service as of September 30, 2025.

Sentiment

Score: 9

Explanation: The filing reports exceptionally strong financial performance across key metrics, including significant revenue, gross profit, net income, and Adjusted EBITDA growth. The company also raised its full-year guidance and achieved a major industry standard compliance with its XSPCT™ analyzer. The strategic pivot to data analytics is yielding high-margin growth, and the Chemistry segment is gaining market share despite industry headwinds. The only minor negative is the increase in SG&A as a percentage of revenue and the delay in VeraCal market demand due to EPA amendments, but these are overshadowed by the overwhelming positives.

Positives

• Gross profit increased by 95% to $17.8 million in Q3 2025, demonstrating strong profitability.
• Net income surged by 704% to $20.4 million in Q3 2025, significantly improving bottom-line performance.
• Adjusted EBITDA grew by 142% to $11.7 million in Q3 2025, marking the twelfth consecutive quarter of improvement.
• Data Analytics segment revenue increased by 232% to $8.9 million in Q3 2025, with a high gross profit margin of 71%.
• Chemistry Technologies external revenue grew by 43% in Q3 2025, indicating market share expansion despite industry contraction.
• The company raised its full-year 2025 guidance for both total revenues (to $220-$225 million) and Adjusted EBITDA (to $35-$40 million).
• A $12.6 million non-cash tax benefit was recognized in Q3 2025, indicating a positive outlook for generating future taxable income.
• The XSPCT™ analyzer achieved compliance with GPA 2172, a significant industry standard for oil and gas custody transfer.
• PWRtek™ assets, acquired in Q2 2025, generated $6.1 million in Q3 2025 revenue with an impressive 89% gross profit margin and are fully operational.
• The company has a strong Data Analytics recurring revenue backlog of $148 million through 2031 from Power Services lease agreements.
• Stock price growth of 337% was noted between October 30, 2023, and October 30, 2025.

Negatives

• Related party chemistry revenues decreased by 18% in Q3 2025, impacted by reduced fleet count utilization.
• Selling, General and Administrative (SG&A) expense increased to $7.4 million (13% of revenues) in Q3 2025 from $5.7 million (11% of revenues) in Q3 2024, primarily due to higher professional fees and personnel costs.
• The EPA's proposed amendments in December 2024 delayed market demand for the VeraCal flare measurement solution.

Risks

• Forward-looking statements are inherently subject to risks and uncertainties, and actual results and outcomes may differ materially from those discussed.
• The company is unable to reconcile forward-looking non-GAAP financial measures to the most directly comparable GAAP financial measures without unreasonable efforts due to the inability to predict certain items like stock-based compensation, interest costs, and revaluation of liabilities.
• Market conditions, such as the 25% year-over-year decline in North American frac fleets, can negatively impact related party chemistry purchases and overall segment revenues.

Future Outlook

Flotek Industries increased its 2025 guidance, now expecting total revenues between $220 million and $225 million and Adjusted EBITDA between $35 million and $40 million, reflecting strong year-to-date performance and a positive outlook for the fourth quarter. The company anticipates 2026 revenues attributable to PWRtek™ to exceed $27 million, and aims to have 25-35 XSPCT™ units in service by year-end, targeting expansion to over 200 potential installations.

Management Comments

• "Flotek delivered an outstanding third quarter, highlighted by reporting total Company gross profit margin of 32%." Dr. Ryan Ezell, CEO.
• "Throughout the quarter, we continued successfully executing our corporate strategy to transform Flotek into a data-driven technology enterprise." Dr. Ryan Ezell, CEO.
• "Our Data Analytics segment delivered quarterly revenue comparable to the full year 2024, reflecting accelerated adoption of our advanced analytics solutions supporting the industrial pivot within the energy infrastructure sector." Dr. Ryan Ezell, CEO.
• "Our Chemistry Technologies segment continued to expand market share, driven by strong demand for our innovative chemical solutions that enhance reservoir performance." Dr. Ryan Ezell, CEO.
• "Our third quarter results underscore the strength in each of our segments and demonstrate our disciplined execution and steadfast commitment to creating value for our customers and shareholders even in challenging market conditions." Dr. Ryan Ezell, CEO.

Industry Context

The company's Chemistry Technologies segment demonstrated resilience by expanding market share and growing external revenue by 43% despite a significant 25% year-over-year decline in North American frac fleets, indicating strong demand for its specialized chemistry solutions in a challenging market. The substantial growth in the Data Analytics segment reflects a broader industry trend towards digital transformation, data-driven solutions, and enhanced operational efficiency within the energy infrastructure sector. The XSPCT™ analyzer's compliance with GPA 2172 addresses a critical need for accurate and standardized custody transfer in the oil and gas industry, positioning the company favorably within this evolving landscape.

Comparison to Industry Standards

• The XSPCT™ analyzer is the first optical spectrometer to comply with GPA 2172 (O&G Custody Transfer Standard), setting a new benchmark for digital valuation of hydrocarbons.
• XSPCT™ units in an Eagleford test exceeded 95% pass rates for methane, ethane, propane, and higher hydrocarbons, demonstrating high precision comparable to online Gas Chromatography (GC) instruments.
• VeraCal was the first EPA approved alternative measurement solution for flaring, differentiating Flotek's flare measurement system in environmental compliance.
• The Chemistry Technologies segment achieved 54% growth in external chemistry revenue year-to-date 2025 versus 2024, despite a 24% drop in average frac fleet count, indicating significant market share gains in a contracting industry.

Related Party Transactions

• Related party revenues for Chemistry Technologies decreased 18% to $26,956 thousand in Q3 2025 compared to Q3 2024.
• Related party chemistry purchases were negatively impacted by reduced frac fleet count utilization.
• The reduction in related party chemistry sales resulted in a 28% increase in revenues attributable to the minimum chemistry purchase requirement in the long-term supply agreement with ProFrac.
• Accounts receivable, related party, net was $44,831 thousand at September 30, 2025.
• Accrued liabilities, related party was $7,248 thousand at September 30, 2025.
• Interest payable, related party was $1,008 thousand at September 30, 2025.
• Note payable related party was $39,560 thousand at September 30, 2025.
• The company's contract assets arose from fixed, non-refundable consideration in the form of convertible notes issued to ProFrac in connection with the ProFrac Agreement.

Stakeholder Impact

• Shareholders: Positive impact due to strong financial performance, increased guidance, significant stock price growth (337% over 2 years), and strategic advancements in high-margin segments.
• Customers: Enhanced value proposition through advanced analytics solutions (Data Analytics) and innovative chemical solutions (Chemistry Technologies) that improve operational efficiency and reservoir performance. Compliance with GPA 2172 for XSPCT™ reduces barriers to adoption and ensures high precision.
• Employees: Continued growth and strategic transformation likely provide stability and opportunities, though increased personnel costs contributed to higher SG&A.
• Creditors: Improved financial health, particularly the 12 consecutive quarters of Adjusted EBITDA improvement, strengthens the company's leverage profile and debt service capacity.

Next Steps

• Host an earnings conference call on Wednesday, November 5, 2025, at 9:00 a.m. CDT (10:00 a.m. EDT).
• Targeting expansion to over 200 potential XSPCT™ installations across multiple customers.
• On target to have a total of 25-35 XSPCT™ units placed into service by year-end.
• Attend the Permian Basin BBQ Cookoff on November 11-12, 2025, in Midland, TX.
• Attend the INVEST Houston 2nd Edition on November 20, 2025, in Houston, TX.
• Attend the DEP NY Executive Series on December 3, 2025, in New York City, NY.
• Attend the 14th Annual ROTH Deer Valley Event on December 10-13, 2025, in Park City, UT.
• Attend the Northland Growth Conference on December 16, 2025 (Virtual).

Key Dates

Recommendation

The company delivered exceptional Q3 2025 results with substantial growth across all key financial metrics, including a 95% increase in gross profit and a 704% surge in net income. The strategic pivot towards high-margin Data Analytics is proving highly successful, with the segment's revenue growing 232% and contributing significantly to overall profitability. The Chemistry Technologies segment also demonstrated resilience by gaining market share despite industry headwinds. The upward revision of full-year 2025 guidance, the achievement of GPA 2172 compliance for the XSPCT™ analyzer, and a robust recurring revenue backlog for Data Analytics indicate strong future prospects and operational excellence. These factors, combined with a 337% stock price growth over the past two years, suggest a compelling investment opportunity.

Keywords

Flotek Industries, FTK, Q3 2025 earnings, financial results, Data Analytics, Chemistry Technologies, energy solutions, oil and gas, gross profit growth, Adjusted EBITDA, revenue guidance, GPA 2172, XSPCT, PWRtek, custody transfer, frac fleets, SEC filing